Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 221Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

HMPL-013 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Unresectable Metastatic Colorectal Cancer × Clear all
NCT04866108 2022-08-18

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Beijing Friendship Hospital

Phase 2 Unknown
49 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

NCT05068206 2021-10-20

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
120 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

NCT04160416 2019-11-19

TRICAP

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
48 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡